Avtar Dhillon, MD | President & Executive Chairman
Dr. Dhillon is a life sciences entrepreneur with more than 20 years’ experience building public companies through mergers and acquisitions, leading innovation in scientific, engineering and farming enterprises, securing government grants and NGO funding (more than US$75 million to date), and building dominant IP portfolios through partnering. During his tenure as President and CEO at Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Dr. Dhillon led the turnaround of the company through restructuring and acquisitions. Under his leadership, Inovio completed financing totaling over US$250 million and several licensing deals with global pharma leaders, such as Merck, Wyeth (now Pfizer), and Roche. Before joining Inovio, he was Vice President of MDS Capital Corp. (now Lumira Capital Corp.), one of North American’s leading healthcare venture capital organizations. Dr. Dhillon practiced family medicine for over 12 years and currently sits on the board of the Cannabis Association of Canada. He has a BSc (Honours) in Human Physiology and an MD from the University of British Columbia.
Jim DeMesa, MD, MBA | CEO
Dr. DeMesa has 27 years of experience in biotech product development, clinical and regulatory management, and partnerships with pharmaceutical, biotech, and medical device companies. He has raised more than $150 million to advance product development into clinical stage, regulatory approval, and commercialization. He is the former CEO of two public biotech companies: Migenix and GenSci Regeneration Sciences (now part of Integra LifeSciences). Dr. DeMesa also currently serves as director for two biotech companies: OncoSec and Induce Biologics. Previously, he was Vice President, Medical and Regulatory Affairs at Biodynamics International (now part of RTI Surgical) and Bentley Pharmaceuticals (now part of Teva Pharmaceuticals). Dr. DeMesa received his BA in Chemistry, MD, and MBA from the University of South Florida.
Lisa Sanford | Interim Chief Financial Officer
Ms. Sanford has 30 years of diversified experience in finance and accounting in the life sciences, biotechnology and pharmaceutical industries. Prior to taking on the role of Interim CFO, she served as our Vice President of Finance and has worked with us as an independent consultant since May 2017. Ms. Sanford also served as an audit senior manager at Ernst & Young LLP, where she was involved in multiple IPOs and business combinations. She received her Bachelor’s degree in Accounting from Lehigh University and is a Certified Public Accountant.
Alain Rolland, PharmD, PhD | Executive Vice President & Chief Development Officer
Dr. Rolland brings over 30 years of international leadership experience in pharmaceutical and biotech companies. He has focused on the discovery and development of biologics and small molecules in a variety of therapeutic areas including immuno-oncology, cardiovascular and hematological disorders, dermatology, and infectious disease vaccines. Prior to joining EHP, Dr. Rolland was a co-founder and served as CEO, President and Director of CHIME BioTherapeutics, Executive Vice President and Chief Scientific Officer at HUYA Bioscience International, Executive Vice President, Product Development at Vical, and Senior Vice President, Preclinical R&D, Head of The Woodlands Center of Valentis. Dr. Rolland has published over 90 scientific articles and book chapters, and is editor of three scientific books. He is a member of several scientific societies, the founding Editor-in-Chief of Current Pharmaceutical Biotechnology, and an editorial board member of several journals. He is also the recipient of the Fellowship Award from the American Association of Pharmaceutical Scientists. Dr. Rolland earned his doctorate degree in Pharmacy (Pharm.D.) and in Pharmaceutical Sciences (Ph.D.) from Rennes University, France.
Joachim P.H. Schupp, MD, Dr. med. | Chief Medical Officer
Dr. Schupp has over 30 years of international pharmaceutical industry experience in all phases of drug development and several therapeutic areas. He directed multiple Phase I – IV clinical studies and led multiple international cross-functional project teams at Ciba-Geigy and Novartis Pharmaceuticals in Switzerland, which resulted in worldwide approval of several New Drug Applications (NDAs), Biologics License Applications (BLAs) and supplemental applications for small molecule drugs, biologics and devices currently on the market. Dr. Schupp also served as Vice President, Clinical & Regulatory Affairs at HUYA Bioscience International, Chief Medical Officer at Imprimis/Transdel Pharmaceuticals, Inc., Vice President, Clinical Development at Apricus Biosciences, Inc., Vice President, Medical Affairs at Adventrx Pharmaceuticals, Inc. and Vice President, Clinical Data Services at ProSanos, Inc. Prior to joining EHP, Dr. Schupp managed his own consulting business (MEQVal), providing services as a medical monitor and drug safety physician. Dr. Schupp received his MD and doctorate (Dr. med.) from Freie Universität Berlin in Germany and practiced medicine in Germany, South Africa, UK and Switzerland.
Nancy Coulson, MBA | Vice President, Regulatory and Quality Affairs
Ms. Coulson has nearly 30 years of experience in providing strategic counsel for regulatory, clinical, and quality affairs. As a senior advisor for medical device and pharmaceutical companies, she manages US and international regulatory documents, briefing packages, and global regulatory dossiers across multiple product categories. Ms. Coulson has also completed several successful pre-approval inspections for new drug and device manufacturing facilities. Most recently, she was Worldwide Director, Regulatory Affairs at Cordis, a Johnson & Johnson company, where she provided strategic direction on global regulatory submissions. She also held scientific and senior regulatory positions at Bristol-Myers Squibb, Bausch & Lomb, GenSci, and Migenix. She received her MBA from Chapman University.
Eduardo Muñoz, PhD, MD | Chief Scientific Officer
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology and Immunology of the University of Córdoba (Spain) and Director of the inflammation and cancer research group at the Institute Maimonides for Biomedical Research of Córdoba. Dr. Muñoz has more than 30 years of experience in biomedical research, and is the author of nearly 200 articles, patents, and book chapters with almost 5,000 citations. He is an expert in the mechanism of actions of cannabinoids and endocannabinoids as well as the development of cannabinoid-based new chemical entities. Dr. Muñoz belongs to the editorial board of several scientific journals and is a co-founder of two biotech companies, VivaCell Biotechnology (Spain) and Glactone Pharma AB (Sweden). He received a PhD in Medicine and Surgery at the University of Córdoba and was an associate researcher at Tufts University in Boston, and at the Institute Pasteur in Paris.
Giovanni Appendino, PhD | Scientific Advisor
Dr. Appendino has studied cannabis and cannabinoids for more than 15 years and is regarded by the global scientific community as one of the world’s most influential thought leaders in cannabinoid research. He is the Director of Research and Development at Indena SpA and Professor of Pharmaceutical Chemistry at the University of Eastern Piedmont in Italy. Dr. Appendino was the local coordinator of three European research programs, and his research on natural products chemistry focuses on medium-sized cyclic compounds, such as cannabinoids. He also serves as Editor in Chief of the scientific journal Fitoterapia, and belongs to the publishing advisory board of several journals for organic chemistry and natural products. Dr. Appendino authored more than 250 articles and 10 book chapters, and holds six patents (four related to cannabinoids).